Terminated × Interventional × Waldenstrom Macroglobulinemia × Clear all ZUMA-25
Phase 2 Terminated
19 enrolled 28 charts
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Phase 2 Terminated
21 enrolled 11 charts
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
Phase 1 Terminated
15 enrolled 12 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia
Phase 1 Terminated
13 enrolled 13 charts
Dasatinib In Waldenström Macroglobulinemia
Phase 1 Terminated
3 enrolled 13 charts
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
Daratumumab Plus Ibrutinib in Patients With WaldenstrÓ§m's Macroglobulinemia
Phase 2 Terminated
1 enrolled 8 charts
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
Phase 1 Terminated
5 enrolled
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Phase 1/2 Terminated
210 enrolled
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase 1 Terminated
10 enrolled
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Phase 1/2 Terminated
46 enrolled 29 charts
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Phase 1 Terminated
2 enrolled 6 charts
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
Phase 1 Terminated
4 enrolled
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Phase 1/2 Terminated
39 enrolled
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
Phase NA Terminated
1 enrolled 3 charts
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Phase 2 Terminated
66 enrolled 14 charts
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
Phase 2 Terminated
10 enrolled
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Phase 1 Terminated
8 enrolled
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Phase 2 Terminated
4 enrolled 12 charts
8400-401
Phase 1/2 Terminated
31 enrolled 18 charts
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Phase NA Terminated
25 enrolled 15 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Bridalveil
Phase 3 Terminated
475 enrolled 9 charts
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1/2 Terminated
81 enrolled 16 charts
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
1 enrolled
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Phase 2 Terminated
14 enrolled 11 charts
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase 1/2 Terminated
6 enrolled 10 charts
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Phase 2 Terminated
3 enrolled 10 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
Phase 2 Terminated
62 enrolled 8 charts
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
Phase 2 Terminated
5 enrolled 8 charts
A Phase II Study of Doxycycline in Relapsed NHL
Phase 2 Terminated
7 enrolled 5 charts
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1/2 Terminated
46 enrolled 12 charts
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Phase 1 Terminated
7 enrolled 8 charts
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Phase 1 Terminated
10 enrolled
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia
Phase 2 Terminated
3 enrolled 4 charts
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia
Phase 2 Terminated
16 enrolled 10 charts
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1 Terminated
5 enrolled
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Phase 1 Terminated
72 enrolled
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
Phase NA Terminated
9 enrolled
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Terminated
32 enrolled 7 charts
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Terminated
36 enrolled
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Phase 1 Terminated
2 enrolled
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
Phase NA Terminated
30 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Terminated
74 enrolled